The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer

Acta Radiologica

Volumn 51, Issue 8, 2010, Pages 859-865

  Ahn, Jhii Hyun ^a   Son, Eun Ju ^a   Kim, Jeong Ah ^a   Youk Jr , Ji Hyun ^a   Kim, Eun Kyung ^a   Kwak, Jin Young ^a   Ryu, Young Hoon ^b   Jeong, Joon ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Department of Nuclear Medicine ^*  (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Metastasis; Staging

Indexed keywords

AXILLARY LYMPH NODES; BREAST CANCER; COMBINED ANALYSIS; DIAGNOSTIC ACCURACY; FDG-PET; FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHIES; LENGTH-TO-WIDTH RATIO; LYMPH NODE METASTASIS; METASTASIS; METASTATIC LYMPH NODES; PROGNOSTIC FACTORS; SENTINEL LYMPH NODES; STAGING; STANDARDIZED UPTAKE VALUES;

DISEASES; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

BODY FLUIDS;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AXILLA; BREAST TUMOR; CANCER STAGING; ECHOGRAPHY; ECHOMAMMOGRAPHY; EVALUATION; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, MAMMARY;

EID: 77956513731     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841851.2010.501342     Document Type: Article

References (25)

1. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin 2006;56:37-47.
2. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 2004;31: S97 - 102.
3. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66:136-138
4. Shaw JH, Rumball EM. Complications and local recurrence following lymphadenectomy. Br J Surg 1990;77:760-764
5. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720
6. Borqstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-283
7. Chaqpar AB, Martin RC, Scoqqins CR, Carlson DJ, Laidley AL, El-Eid SE, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 2005;138:56-63.
8. Duchesne N, Jaffey J, Florack P, Duchesne S. Redefi ning ultrasound appearance criteria of positive axillary lymph nodes. Can Assoc Radiol J 2005;56:289-296
9. Damera A, Evans AJ, Cornford EJ, Wilson AR, Burrell HC, James JJ, et al. Diagnosis of axillary nodal metastasis by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer 2003;89:1310-1313
10. Yang WT, Ahuja A, Tang A, Suen M, King W, Metreweli C. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med 1996; 15:241-246
11. Vaidya JS, Vyas JJ, Thakur MH, Khandelwal KC, Mittra I. Role of ultrasonography to detect axillary node involvement in operable breast cancer. Eur J Surg Oncol 1996; 22:140-143
12. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fl uoro-D-glucose PET. Radiology 1993;187: 743-750
13. Utech CI, Young CS, Winter PF. Prospective evaluation of fl uorine-18 fl uorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunohistochemistry. Eur J Nucl Med 1996; 23:1588-1593
14. Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fl uorine-18)-fl uoro-2-deoxy- D-glucose. J Natl Cancer Inst 1996;88:1204-1209
15. Khalkhali I, Diqqles LE, Taillefer R, Vandestreek PR, Peller PJ, Abdel-Nabi HH. Procedure guideline for breast scintigraphy. Society of Nuclear Medicine. J Nucl Med 1999;40:1233-1235
16. Lumachi F, Tregnaghi A, Ferretti G, Povolato M, Marzola MC, Zucchetta P, et al. Accuracy of ultrasonography and 99mTc-sestamibi scintimammography for assessing axillary lymph node status in breast cancer patients. A prospective study. Eur J Surg Oncol 2006;32:933-936
17. Motomura K, Inaji H, Komoike Y, Kasugai T, Nagumo S, Hasegawa Y, et al. Gamma probe and ultrasonographically- guided fi ne-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol 2001; 27:141-145
18. Alvarez S, Añorbe E, Alcorta P, López F, Alonso I, Cortés J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. Am J Roentgenol 2006;186:1342-1348
19. Deurloo EE, Tanis PJ, Gilhuijs KG, Muller SH, Krö ger R, Peterse JL, et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 2003;39:1068-1073
20. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Glovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fl uoro-2-deoxy-D-glucose- positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:630-635
21. Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hajiike M, et al. Preoperative FDG-PET for axillary meta stases in patients with breast cancer. Arch Surg 2006;141:783-789
22. Gopalan D, Bomanji JB, Costa DC, Ell PJ. Nuclear medi cine in primary breast cancer imaging. Clin Radiol 2002;57:565-574
23. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-3502
24. Feuardent J, Soret M, de Dreuille O, Foehrenbach H, Buvat I. Reliability of SUV estimates in FDG PET as a function of acquisition and processing protocols. Nuclear Science Symposium Conference Record 2003;4:2877-2881
25. Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003;44:1044-1050